5-Chloro-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
Names and Identifiers of 1000340-13-5
CAS Number |
1000340-13-5 |
|---|---|
MDL Number |
MFCD09880102 |
IUPAC Name |
5-chloro-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde |
InChI |
InChI=1S/C9H7ClN2O/c1-5-8(10)2-7-6(4-13)3-11-9(7)12-5/h2-4H,1H3,(H,11,12) |
InChIKey |
SRHIQFRRDZIXSE-UHFFFAOYSA-N |
Canonical SMILES |
CC1=C(C=C2C(=CNC2=N1)C=O)Cl |
UNSPSC Code |
12352100 |
Physical and chemical properties of 1000340-13-5
Density |
1.4±0.1 g/cm3 |
|---|---|
Exact Mass |
194.024689 |
H Bond Acceptors |
2 |
H Bond Donors |
1 |
Index of Refraction |
1.716 |
LogP |
2.76 |
Molecular Formula |
C9H7ClN2O |
Molecular Weight |
194.618 |
PSA |
45.75000 |
Safety Information of 1000340-13-5
Applications of 1000340-13-5
5-Chloro-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde has potential applications in:
- Pharmaceuticals: As a lead compound for developing new anticancer agents targeting FGFR pathways.
- Chemical Research: In studies focused on synthesizing novel heterocyclic compounds with varied biological activities.
The unique structure of this compound allows for modifications that can enhance its efficacy and selectivity in biological systems .
Interaction Studies of 1000340-13-5
Studies on the interactions of 5-Chloro-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde with biomolecules have shown that it may intercalate with DNA. This interaction is critical for understanding its mechanism of action as an antiproliferative agent. Molecular docking studies suggest that this compound binds effectively to target sites within DNA structures .
Biological Activity of 1000340-13-5
Research indicates that derivatives of 1H-pyrrolo[2,3-b]pyridines, including 5-Chloro-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde, exhibit notable biological activities. These compounds have been studied for their potential as inhibitors of fibroblast growth factor receptors (FGFRs), which play a crucial role in cancer progression. For instance, certain derivatives demonstrated potent inhibitory effects against FGFR1, FGFR2, and FGFR3, making them promising candidates for cancer therapy .
